All In MedTech

FDA Clearance Tracker · P030019-S006

ORTHOVISC SODIUM HYALURONATE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 28, 2004 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 28, 2004

Approved

Time to decision

180 days

Received Jul 1, 2004. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P030019-S006
Device name
ORTHOVISC SODIUM HYALURONATE
Applicant location
Beford, MA
Received
Jul 1, 2004
Decided
Dec 28, 2004
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P030019

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

APPROVAL TO MODIFY THE LABELING TO INCLUDE SAFETY INFORMATION CONCERNING A REPEAT COURSE OF TREATMENT OF ORTHOVISC.

Source documents

Other decisions for Anika Therapeutics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.